NEW YORK (GenomeWeb News) – Metabolon said today that Pfizer’s Bioprocess R&D Group is using the firm’s metabolomics technology in analyzing cellular metabolism in the biopharmaceutical production process.
 
Pfizer will use the biochemical profiling technology, called mVision, to analyze samples from bioreactors, said Research Triangle Park, NC-based Metabolon. The tool will enable researchers to identify essential nutrients that are depleted and unearth toxic metabolites in the cells.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.